<DOC>
	<DOCNO>NCT02235077</DOCNO>
	<brief_summary>The primary objective study test hypothesis high-dose spironolactone lead great proportional reduction NT-proBNP level randomization 96 hour standard care .</brief_summary>
	<brief_title>Study High-dose Spironolactone v . Placebo Therapy Acute Heart Failure</brief_title>
	<detailed_description>Mineralocorticoid receptor antagonist ( MRA ) therapy recommend stable chronic systolic heart failure ( HF ) post-infarction HF patient improve morbidity mortality . MRA therapy AHF high dos less well study . The effectiveness safety early high dose MRA therapy AHF support single-blind study show low risk worsen renal function need loop diuretic , improve congestion . MRA therapy AHF may improve outcome relieve congestion high dose natriuretic property , addition prevent deleterious effect exacerbation neuro-hormonal activation loop diuretic . This randomized , double blind , placebo-controlled study high-dose spironolactone vs. placebo ( patient receive MRA home ) low-dose spironolactone ( patient already receive low-dose spironolactone ) AHF , enroll 360 participant approximately 30 clinical center . After obtain informed consent , subject fulfill inclusion criterion none exclusion criterion randomize . Randomization perform use procedure determine Coordinating Center ( CC ) . - Patients receive MRA therapy baseline randomize receive either spironolactone 100 mg placebo daily 96 hour . - Patients already receive low-dose spironolactone baseline ( 12.5 mg 25 mg daily ) randomize 100 mg 25 mg spironolactone daily 96 hour . Within 24 hour prior randomization , study participant undergo : - Medical History - Review medication include pre-hospital loop diuretic , MRA , potassium dos - Physical examination , vital sign body weight - Measurement creatinine , blood urea nitrogen ( BUN ) , electrolytes - Dyspnea Relief Assessments ( 7-point Likert Visual Analog Scale ) - Serum pregnancy test woman childbearing potential - Collection sample measurement NT-proBNP level ( Core Lab ) Study drug initiate follow : - Patients receive MRA therapy baseline : 4x25 mg study capsule daily ; start dose 100 mg spironolactone placebo ; dose adjustment require , active capsule adjust pharmacy achieve require dose . - Patients already receive low-dose spironolactone baseline : 4x25 mg study capsule daily ; one capsule contain 25 mg spironolactone 3x25 mg study capsule contain spironolactone placebo ; dose adjustment require , active capsule adjust pharmacy achieve require dose . Patients follow every 24 hour follow randomization 96 hour . Study drug administer daily 96 hour . Study drug administration time anchored time randomization . Dose adjustment ( continue , hold , stop ) permit accord serum K+ renal function . Assessment 24 hour post randomization include : Review medication , body weight , fluid intake/urine output , creatinine , blood urea nitrogen ( BUN ) , electrolytes , adverse event . If 24 hour assessment also day discharge , include : - Physical exam / Vital sign - Dyspnea Relief ( 7-Point Likert VAS ) worksheets - Biomarkers ( NT-proBNP ) ( Core Lab ) Assessment 48 hour post randomization include : Review medication , physical exam/vital sign , body weight , fluid intake/urine output , Dyspnea Relief ( 7-Point Likert VAS ) worksheet , creatinine , blood urea nitrogen ( BUN ) , electrolytes , biomarker level ( NT-proBNP ) Core Lab . Assessment 72 hour post randomization include : Review medication , body weight , fluid intake/urine output , creatinine , blood urea nitrogen ( BUN ) , electrolytes , adverse event . If 72 hour assessment also day discharge , include : - Physical exam / Vital sign - Dyspnea Relief ( 7-Point Likert VAS ) worksheets - Biomarkers ( NT-proBNP ) ( Core Lab ) Assessment 96 hour post randomization include : Review medication , physical exam/vital sign , body weight , fluid intake/urine output , creatinine , blood urea nitrogen ( BUN ) , electrolytes , Dyspnea Relief ( 7-Point Likert VAS ) , biomarker level ( NT-proBNP ) Core Lab . If patient clinically euvolemic less 96 hour , investigator may consider change loop diuretic oral dose . Study drug discontinue 96 hour use MRA leave treat physician 's discretion . Assessment Discharge : If discharge occur 96 hour assessment prior 30 day follow-up telephone call , follow document : Medication review ( prescribed medication time discharge ) , body weight ( available ) , creatinine , blood urea nitrogen ( BUN ) , electrolytes ( available ) , adverse event . Ejection fraction data obtain echocardiogram within 6 month prior randomization . Those patient echocardiogram record within time frame get echocardiogram , nuclear perfusion study , MRI , MUGA perform prior 96 hour in-hospital assessment ascertain ejection fraction . Follow-up Telephone Call Day 30 : All participant contact telephone day 30 ( +3 day ) follow randomization assess tertiary endpoint , include medication use adverse event . Follow-up Telephone Call Day 60 : All participant contact telephone day 60 ( +/-3 day ) follow randomization ass vital status . During consent process , patient ask interested donating sample data research purpose via biorepository and/or genetic study . Based site IRB preference , optional part study may incorporate main consent may separate consent IRB application .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Male female patient ≥21 year old Admitted hospital AHF least 1 symptom ( dyspnea , orthopnea , fatigue ) 1 sign ( rales auscultation , peripheral edema , ascites , pulmonary vascular congestion chest radiography ) congestion Patient must randomize within 24 hour first IV diuretic dose administer current episode decompensation ( regardless diuretic give e.g . office , ED , ambulance , hospital etc . ) Estimated GFR ≥30 mL/min/1.73m2 determine MDRD equation Serum K+ ≤5.0 mmol/L enrollment NTproBNP ≥1000 pg/mL BNP ≥250 pg/mL , measure within 24h randomization Not MRA lowdose spironolactone ( 12.5 mg 25 mg daily ) baseline Taking eplerenone &gt; 25 mg spironolactone baseline eGFR &lt; 30 ml/min/1.73m2 Serum K+ &gt; 5.0 mmol/L . If repeat measurement within enrollment window &lt; 5.0 , patient consider inclusion . Systolic blood pressure &lt; 90 mmHg Hemodynamically significant arrhythmia defibrillator shock within 1 week Acute coronary syndrome currently suspect within past 4 week Severe liver disease ( ALT AST &gt; 3 x normal , alkaline phosphatase bilirubin &gt; 2x normal ) Active infection ( current use oral IV antimicrobial agent ) Active gastrointestinal bleeding Active malignancy nonmelanoma skin cancer Current plan mechanical circulatory support within 30 day Post cardiac transplant list transplant expect receive one within 30 day Current inotrope use Complex congenital heart disease Primary hypertrophic cardiomyopathy , infiltrative cardiomyopathy , acute myocarditis , constrictive pericarditis tamponade Previous adverse reaction MRAs Enrollment another randomize clinical trial index hospitalization</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Aldactone</keyword>
</DOC>